The mission of the Alzheimer’s Association Research Roundtable (AARR) is to advance the research, development and management of new treatments for Alzheimer’s disease.
The AARR member companies provide leadership and direction to the organization’s various activities. Begun in 2003 with four members, the Research Roundtable now includes more than 20 corporate members, whose scientists participate in the Roundtable to contribute to and benefit from the state-of-the-field scientific discourse, debate, and information sharing in order to advance the field of Alzheimer’s research and development. Additional participants include invited investigators from academia and such international government organizations as the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and the National Institutes of Health.